Abstract：Objective: To explore the effect of Qizhen capsule on T lymphocyte subsets,tumor markers and prognosis of breast cancer. Methods: Eighty patients with breast cancer who received treatment at our hospital from January 2019 to January 2021 were selected for this study.They were randomly divided into a control group and an observation group,with 40 patients in each group.Both groups received the EC chemotherapy intervention (cyclophosphamide+doxorubicin+fluorouracil).Additionally,the observation group received Qizhen capsule as oral treatment.Both groups were treated continuously for 6 weeks.The study compared the blood routine status,T lymphocyte subpopulations (CD3+,CD4+,CD8+),and tumor marker indicators (carcinoembryonic antigen (CEA),carbohydrate antigen 153 (CA153),and cancer antigen 125 (CA125) levels between the two groups.As of the follow-up on February 28,2023,the study analyzed the difference in median survival time between the two groups. Results: Before treatment,there were no significant differences in red blood cells,white blood cells,and platelets between the two groups (P>0.05).After treatment,the difference in white blood cell and platelet counts before and after treatment in the observation group was greater than in the control group (P<0.05).Before treatment,there were no significant differences in CD3+,CD4+,and CD8+ between the two groups (P>0.05).After treatment,the difference in CD3+ and CD4+ before and after treatment in the observation group was greater than in the control group (P<0.05).Before treatment,there were no significant differences in CEA,CA153,and CA125 between the two groups (P>0.05).After treatment,CEA,CA153,and CA125 were decreased in both groups,with the difference in CEA,CA153,and CA125 before and after treatment in the observation group being greater than in the control group (P<0.05).As of February 28,2023,4 patients in the observation group experienced disease recurrence and metastasis,while 11 patients in the control group experienced recurrence and metastasis.Compared with the control group,the observation group had a higher disease-free survival rate,and the survival advantage was more pronounced (χ2=7.195,P=0.007).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Adjuvant treatment with Qizhen capsule can improve the T lymphocyte subsets,tumor markers,and postoperative survival of breast cancer patients,and the treatment is safe.
2023, Vol. 29 
冀公网安备13080202000677号